Biomarkers /
BRCA1 Mutation
Back to Biomarkers List
Overview
BRCA1 Mutation is present in 2.34% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, high grade ovarian serous adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence [4].
Biomarker-Directed Therapies
BRCA1 Mutation is a predictive biomarker for use of olaparib, rucaparib, bevacizumab, and niraparib in patients.
Of the therapies with BRCA1 Mutation as a predictive biomarker, 4 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting.
Fallopian tube carcinoma, malignant ovarian neoplasm, primary peritoneal carcinoma, prostate carcinoma, and malignant peritoneal neoplasm have the most therapies targeted against BRCA1 Mutation or its related pathways [5].
Niraparib +
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens. |
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens. |
Olaparib +
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN) | |
| Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for patients with advanced ovarian cancer (1) with BRCA1/2 deleterious germline mutations who have been treated with three or more prior lines of chemotherapy, and (2) for maintenance treatment with BRCA1/2 deleterious germline or somatic mutations with complete or partial response to first-line chemotherapy. |
Malignant Peritoneal Neoplasm -
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN) | |
| Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy. |
Prostate Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
ATM Mutation, BRCA1 Mutation, BRCA2 Mutation, FANCL Mutation, PALB2 Mutation, ATM Loss, BARD1 Loss, BARD1 Mutation, BRCA1 Loss, BRCA2 Loss, BRIP1 Loss, BRIP1 Mutation, CDK12 Loss, CDK12 Mutation, CHEK1 Loss, CHEK1 Mutation, CHEK2 Loss, CHEK2 Mutation, FANCL Loss, PALB2 Loss, RAD51B Loss, RAD51B Mutation, RAD51C Loss, RAD51C Mutation, RAD51D Loss, RAD51D Mutation, RAD54L Loss, RAD54L Mutation |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. |
Rucaparib +
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious germline or somatic mutations in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious germline or somatic mutations in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. |
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious germline or somatic mutations in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. |
Prostate Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for deleterious BRCA mutations (germline and/or somatic) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. |
Bevacizumab + Olaparib +
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA) | |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA) | |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA) | |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Clinical Trials
BRCA1 Mutation serves as an inclusion eligibility criterion in 149 clinical trials, of which 118 are open and 31 are closed. Of the trials that contain BRCA1 Mutation as an inclusion criterion, 2 are early phase 1 (2 open), 31 are phase 1 (22 open), 19 are phase 1/phase 2 (14 open), 83 are phase 2 (68 open), 1 is phase 2/phase 3 (1 open), 10 are phase 3 (9 open), 1 is phase 4 (1 open), and 2 are no phase specified (1 open).
Trials with BRCA1 Mutation in the inclusion eligibility criteria most commonly target malignant solid tumor, breast carcinoma, ovarian carcinoma, primary peritoneal carcinoma, and fallopian tube carcinoma [5].
Olaparib, niraparib, rucaparib, talazoparib, and carboplatin are the most frequent therapies in trials with BRCA1 Mutation as an inclusion criteria [5].
Significance of BRCA1 Mutation in Diseases
Primary Peritoneal Carcinoma +
BRCA1 is altered in 4.55% of primary peritoneal carcinoma patients with BRCA1 Mutation present in 4.55% of all primary peritoneal carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 23 clinical trials for primary peritoneal carcinoma, of which 16 are open and 7 are closed. Of the trials that contain BRCA1 Mutation and primary peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 8 are phase 2 (4 open), 3 are phase 3 (2 open), and 1 is phase 4 (1 open) [5].
Bevacizumab, olaparib, niraparib, and rucaparib have evidence of efficacy in patients with BRCA1 Mutation in primary peritoneal carcinoma [5].
Fallopian Tube Carcinoma +
BRCA1 is altered in 3.64% of fallopian tube carcinoma patients with BRCA1 Mutation present in 1.82% of all fallopian tube carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 22 clinical trials for fallopian tube carcinoma, of which 15 are open and 7 are closed. Of the trials that contain BRCA1 Mutation and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (4 open), 3 are phase 3 (2 open), and 1 is phase 4 (1 open) [5].
Olaparib, bevacizumab, niraparib, and rucaparib have evidence of efficacy in patients with BRCA1 Mutation in fallopian tube carcinoma [5].
Prostate Carcinoma +
BRCA1 is altered in 1.24% of prostate carcinoma patients with BRCA1 Mutation present in 0.82% of all prostate carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 22 clinical trials for prostate carcinoma, of which 19 are open and 3 are closed. Of the trials that contain BRCA1 Mutation and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 13 are phase 2 (12 open), and 2 are phase 3 (2 open) [5].
Olaparib and rucaparib have evidence of efficacy in patients with BRCA1 Mutation in prostate carcinoma [5].
Malignant Peritoneal Neoplasm +
BRCA1 is altered in 4.55% of malignant peritoneal neoplasm patients with BRCA1 Mutation present in 4.55% of all malignant peritoneal neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant peritoneal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and malignant peritoneal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].
Olaparib has evidence of efficacy in patients with BRCA1 Mutation in malignant peritoneal neoplasm [5].
Malignant Ovarian Neoplasm +
BRCA1 is altered in 7.35% of malignant ovarian neoplasm patients with BRCA1 Mutation present in 4.03% of all malignant ovarian neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and malignant ovarian neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].
Olaparib, bevacizumab, niraparib, and rucaparib have evidence of efficacy in patients with BRCA1 Mutation in malignant ovarian neoplasm [5].
Malignant Solid Tumor +
BRCA1 is altered in 3.21% of malignant solid tumor patients with BRCA1 Mutation present in 2.51% of all malignant solid tumor patients [4].
BRCA1 Mutation is an inclusion criterion in 52 clinical trials for malignant solid tumor, of which 41 are open and 11 are closed. Of the trials that contain BRCA1 Mutation and malignant solid tumor as inclusion criteria, 22 are phase 1 (16 open), 12 are phase 1/phase 2 (7 open), and 18 are phase 2 (18 open) [5].
Breast Carcinoma +
BRCA1 is altered in 3.12% of breast carcinoma patients with BRCA1 Mutation present in 1.9% of all breast carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 38 clinical trials for breast carcinoma, of which 30 are open and 8 are closed. Of the trials that contain BRCA1 Mutation and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (7 open), 6 are phase 1/phase 2 (5 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [5].
Ovarian Carcinoma +
BRCA1 is altered in 7.82% of ovarian carcinoma patients with BRCA1 Mutation present in 4.16% of all ovarian carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 32 clinical trials for ovarian carcinoma, of which 25 are open and 7 are closed. Of the trials that contain BRCA1 Mutation and ovarian carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 9 are phase 1 (6 open), 6 are phase 1/phase 2 (5 open), 11 are phase 2 (9 open), 3 are phase 3 (2 open), and 1 is phase 4 (1 open) [5].
Prostate Adenocarcinoma +
BRCA1 is altered in 1.22% of prostate adenocarcinoma patients with BRCA1 Mutation present in 0.82% of all prostate adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain BRCA1 Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
BRCA1 is altered in 9.01% of high grade ovarian serous adenocarcinoma patients with BRCA1 Mutation present in 4.87% of all high grade ovarian serous adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 11 clinical trials for high grade ovarian serous adenocarcinoma, of which 6 are open and 5 are closed. Of the trials that contain BRCA1 Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].
Non-Small Cell Lung Carcinoma +
BRCA1 is altered in 3.53% of non-small cell lung carcinoma patients with BRCA1 Mutation present in 3.16% of all non-small cell lung carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 9 clinical trials for non-small cell lung carcinoma, of which 7 are open and 2 are closed. Of the trials that contain BRCA1 Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [5].
Pancreatic Carcinoma +
BRCA1 is altered in 2.0% of pancreatic carcinoma patients with BRCA1 Mutation present in 1.47% of all pancreatic carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 9 clinical trials for pancreatic carcinoma, of which 8 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and pancreatic carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].
Endometrial Carcinoma +
BRCA1 is altered in 5.12% of endometrial carcinoma patients with BRCA1 Mutation present in 4.53% of all endometrial carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 8 clinical trials for endometrial carcinoma, of which 7 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and endometrial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].
Pancreatic Adenocarcinoma +
BRCA1 is altered in 2.0% of pancreatic adenocarcinoma patients with BRCA1 Mutation present in 1.47% of all pancreatic adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 8 clinical trials for pancreatic adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (6 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
BRCA1 is altered in 2.16% of adenocarcinoma of the gastroesophageal junction patients with BRCA1 Mutation present in 1.23% of all adenocarcinoma of the gastroesophageal junction patients [4].
BRCA1 Mutation is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].
High Grade Fallopian Tube Serous Adenocarcinoma +
BRCA1 is altered in 3.64% of high grade fallopian tube serous adenocarcinoma patients with BRCA1 Mutation present in 1.82% of all high grade fallopian tube serous adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 7 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 4 are open and 3 are closed. Of the trials that contain BRCA1 Mutation and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (0 open), and 1 is phase 3 (1 open) [5].
Urothelial Carcinoma +
BRCA1 is altered in 5.82% of urothelial carcinoma patients with BRCA1 Mutation present in 5.38% of all urothelial carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].
Small Cell Lung Carcinoma +
BRCA1 is altered in 1.99% of small cell lung carcinoma patients with BRCA1 Mutation present in 1.99% of all small cell lung carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 6 clinical trials for small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRCA1 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [5].
Melanoma +
BRCA1 is altered in 4.97% of melanoma patients with BRCA1 Mutation present in 4.56% of all melanoma patients [4].
BRCA1 Mutation is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [5].
Colorectal Carcinoma +
BRCA1 is altered in 3.68% of colorectal carcinoma patients with BRCA1 Mutation present in 2.76% of all colorectal carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRCA1 Mutation and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].
Head And Neck Carcinoma +
BRCA1 is altered in 3.05% of head and neck carcinoma patients with BRCA1 Mutation present in 2.73% of all head and neck carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 5 clinical trials for head and neck carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].
Gastric Adenocarcinoma +
BRCA1 is altered in 1.98% of gastric adenocarcinoma patients with BRCA1 Mutation present in 1.49% of all gastric adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 5 clinical trials for gastric adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [5].
Gastric Carcinoma +
BRCA1 is altered in 1.96% of gastric carcinoma patients with BRCA1 Mutation present in 1.47% of all gastric carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].
Fallopian Tube Endometrioid Adenocarcinoma +
BRCA1 Mutation is an inclusion criterion in 5 clinical trials for fallopian tube endometrioid adenocarcinoma, of which 2 are open and 3 are closed. Of the trials that contain BRCA1 Mutation and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 2 (0 open), and 1 is phase 3 (1 open) [5].
Primary Peritoneal Serous Adenocarcinoma +
BRCA1 is altered in 4.55% of primary peritoneal serous adenocarcinoma patients with BRCA1 Mutation present in 4.55% of all primary peritoneal serous adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 4 clinical trials for primary peritoneal serous adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and primary peritoneal serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (0 open), and 1 is phase 3 (1 open) [5].
Cervical Carcinoma +
BRCA1 is altered in 3.19% of cervical carcinoma patients with BRCA1 Mutation present in 3.19% of all cervical carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Non-Hodgkin Lymphoma +
BRCA1 is altered in 1.71% of non-hodgkin lymphoma patients with BRCA1 Mutation present in 1.65% of all non-hodgkin lymphoma patients [4].
BRCA1 Mutation is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].
Lymphoma +
BRCA1 is altered in 1.47% of lymphoma patients with BRCA1 Mutation present in 1.42% of all lymphoma patients [4].
BRCA1 Mutation is an inclusion criterion in 4 clinical trials for lymphoma, of which 1 is open and 3 are closed. Of the trials that contain BRCA1 Mutation and lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].
Soft Tissue Sarcoma +
BRCA1 is altered in 0.95% of soft tissue sarcoma patients with BRCA1 Mutation present in 0.6% of all soft tissue sarcoma patients [4].
BRCA1 Mutation is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Hereditary Breast And Ovarian Cancer Syndrome +
BRCA1 Mutation is an inclusion criterion in 4 clinical trials for hereditary breast and ovarian cancer syndrome, of which 1 is open and 3 are closed. Of the trials that contain BRCA1 Mutation and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), 1 is phase 2/phase 3 (1 open), and 1 is no phase specified (0 open) [5].
Bladder Carcinoma +
BRCA1 is altered in 5.98% of bladder carcinoma patients with BRCA1 Mutation present in 5.61% of all bladder carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].
Ovarian Endometrioid Adenocarcinoma +
BRCA1 is altered in 5.69% of ovarian endometrioid adenocarcinoma patients with BRCA1 Mutation present in 4.88% of all ovarian endometrioid adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 3 clinical trials for ovarian endometrioid adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain BRCA1 Mutation and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [5].
Head And Neck Squamous Cell Carcinoma +
BRCA1 is altered in 4.18% of head and neck squamous cell carcinoma patients with BRCA1 Mutation present in 3.65% of all head and neck squamous cell carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [5].
Breast Lobular Carcinoma In Situ +
BRCA1 Mutation is an inclusion criterion in 3 clinical trials for breast lobular carcinoma in situ, of which 1 is open and 2 are closed. Of the trials that contain BRCA1 Mutation and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), and 1 is phase 2/phase 3 (1 open) [5].
Primary Peritoneal Endometrioid Adenocarcinoma +
BRCA1 Mutation is an inclusion criterion in 3 clinical trials for primary peritoneal endometrioid adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 Mutation and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (0 open), and 1 is phase 3 (1 open) [5].
Bladder Urothelial Carcinoma +
BRCA1 is altered in 6.0% of bladder urothelial carcinoma patients with BRCA1 Mutation present in 5.6% of all bladder urothelial carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Squamous Cell Lung Carcinoma +
BRCA1 is altered in 4.85% of squamous cell lung carcinoma patients with BRCA1 Mutation present in 4.45% of all squamous cell lung carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA1 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].
Malignant Ovarian Epithelial Tumor +
BRCA1 is altered in 7.48% of malignant ovarian epithelial tumor patients with BRCA1 Mutation present in 4.11% of all malignant ovarian epithelial tumor patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for malignant ovarian epithelial tumor, of which 1 is open and 1 is closed. Of the trials that contain BRCA1 Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].
Pancreatic Ductal Adenocarcinoma +
BRCA1 is altered in 2.94% of pancreatic ductal adenocarcinoma patients with BRCA1 Mutation present in 2.94% of all pancreatic ductal adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA1 Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].
Esophageal Adenocarcinoma +
BRCA1 is altered in 2.95% of esophageal adenocarcinoma patients with BRCA1 Mutation present in 2.38% of all esophageal adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Malignant Central Nervous System Neoplasm +
BRCA1 is altered in 2.5% of malignant central nervous system neoplasm patients with BRCA1 Mutation present in 2.35% of all malignant central nervous system neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Esophageal Carcinoma +
BRCA1 is altered in 2.53% of esophageal carcinoma patients with BRCA1 Mutation present in 2.07% of all esophageal carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].
Bile Duct Carcinoma +
BRCA1 is altered in 1.73% of bile duct carcinoma patients with BRCA1 Mutation present in 1.53% of all bile duct carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for bile duct carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and bile duct carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Osteosarcoma +
BRCA1 is altered in 1.61% of osteosarcoma patients with BRCA1 Mutation present in 1.21% of all osteosarcoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Clear Cell Renal Cell Carcinoma +
BRCA1 is altered in 0.8% of clear cell renal cell carcinoma patients with BRCA1 Mutation present in 0.53% of all clear cell renal cell carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Gastrointestinal Stromal Tumor +
BRCA1 is altered in 0.43% of gastrointestinal stromal tumor patients with BRCA1 Mutation present in 0.43% of all gastrointestinal stromal tumor patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Ductal Carcinoma In Situ +
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for ductal carcinoma in situ, of which 0 are open and 2 are closed. Of the trials that contain BRCA1 Mutation and ductal carcinoma in situ as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (0 open) [5].
Ewing Sarcoma +
BRCA1 is altered in 0.65% of Ewing sarcoma patients [4].
BRCA1 Mutation is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Anal Carcinoma +
BRCA1 is altered in 7.1% of anal carcinoma patients with BRCA1 Mutation present in 6.51% of all anal carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Ovarian Carcinosarcoma +
BRCA1 is altered in 4.35% of ovarian carcinosarcoma patients with BRCA1 Mutation present in 4.35% of all ovarian carcinosarcoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and ovarian carcinosarcoma as inclusion criteria, 1 is phase 2 (0 open) [5].
Malignant Ovarian Serous Tumor +
BRCA1 is altered in 8.23% of malignant ovarian serous tumor patients with BRCA1 Mutation present in 4.33% of all malignant ovarian serous tumor patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian serous tumor, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and malignant ovarian serous tumor as inclusion criteria, 1 is phase 2 (0 open) [5].
Endometrial Adenocarcinoma +
BRCA1 is altered in 4.87% of endometrial adenocarcinoma patients with BRCA1 Mutation present in 4.27% of all endometrial adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Penile Carcinoma +
BRCA1 is altered in 4.0% of penile carcinoma patients with BRCA1 Mutation present in 4.0% of all penile carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Carcinoma Of Unknown Primary +
BRCA1 is altered in 4.86% of carcinoma of unknown primary patients with BRCA1 Mutation present in 3.62% of all carcinoma of unknown primary patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
BRCA1 is altered in 4.08% of malignant uterine neoplasm patients with BRCA1 Mutation present in 3.62% of all malignant uterine neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Neuroendocrine Carcinoma +
BRCA1 is altered in 3.64% of neuroendocrine carcinoma patients with BRCA1 Mutation present in 3.41% of all neuroendocrine carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ampulla Of Vater Carcinoma +
BRCA1 is altered in 3.18% of ampulla of vater carcinoma patients with BRCA1 Mutation present in 3.18% of all ampulla of vater carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Lung Carcinoma +
BRCA1 is altered in 3.45% of lung carcinoma patients with BRCA1 Mutation present in 3.1% of all lung carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Intestinal Neoplasm +
BRCA1 is altered in 3.67% of malignant intestinal neoplasm patients with BRCA1 Mutation present in 2.74% of all malignant intestinal neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Colorectal Adenocarcinoma +
BRCA1 is altered in 3.66% of colorectal adenocarcinoma patients with BRCA1 Mutation present in 2.73% of all colorectal adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Diffuse Large B-Cell Lymphoma +
BRCA1 is altered in 2.9% of diffuse large B-cell lymphoma patients with BRCA1 Mutation present in 2.7% of all diffuse large B-cell lymphoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Glioblastoma +
BRCA1 is altered in 2.86% of glioblastoma patients with BRCA1 Mutation present in 2.6% of all glioblastoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Anaplastic Astrocytoma +
BRCA1 is altered in 2.86% of anaplastic astrocytoma patients with BRCA1 Mutation present in 2.57% of all anaplastic astrocytoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Glioma +
BRCA1 is altered in 2.64% of glioma patients with BRCA1 Mutation present in 2.49% of all glioma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Multiple Myeloma +
BRCA1 is altered in 2.37% of multiple myeloma patients with BRCA1 Mutation present in 2.37% of all multiple myeloma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Small Intestinal Neoplasm +
BRCA1 is altered in 3.59% of malignant small intestinal neoplasm patients with BRCA1 Mutation present in 2.24% of all malignant small intestinal neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Invasive Breast Carcinoma +
BRCA1 is altered in 3.14% of invasive breast carcinoma patients with BRCA1 Mutation present in 1.86% of all invasive breast carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and invasive breast carcinoma as inclusion criteria, 1 is no phase specified (0 open) [5].
Leiomyosarcoma +
BRCA1 is altered in 2.52% of leiomyosarcoma patients with BRCA1 Mutation present in 1.8% of all leiomyosarcoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Mixed Mesodermal (Mullerian) Tumor +
BRCA1 is altered in 2.01% of malignant mixed mesodermal (mullerian) tumor patients with BRCA1 Mutation present in 1.75% of all malignant mixed mesodermal (mullerian) tumor patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [5].
Malignant Esophagogastric Neoplasm +
BRCA1 is altered in 2.18% of malignant esophagogastric neoplasm patients with BRCA1 Mutation present in 1.68% of all malignant esophagogastric neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Neuroblastoma +
BRCA1 is altered in 2.98% of neuroblastoma patients with BRCA1 Mutation present in 1.63% of all neuroblastoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Rhabdomyosarcoma +
BRCA1 is altered in 1.59% of rhabdomyosarcoma patients with BRCA1 Mutation present in 1.59% of all rhabdomyosarcoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
BRCA1 is altered in 1.66% of B-cell non-hodgkin lymphoma patients with BRCA1 Mutation present in 1.57% of all B-cell non-hodgkin lymphoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bile Duct Adenocarcinoma +
BRCA1 is altered in 1.73% of bile duct adenocarcinoma patients with BRCA1 Mutation present in 1.53% of all bile duct adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Cholangiocarcinoma +
BRCA1 is altered in 1.73% of cholangiocarcinoma patients with BRCA1 Mutation present in 1.53% of all cholangiocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Gastric Neoplasm +
BRCA1 is altered in 1.96% of malignant gastric neoplasm patients with BRCA1 Mutation present in 1.47% of all malignant gastric neoplasm patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +
BRCA1 is altered in 1.47% of mature T-cell and NK-cell non-hodgkin lymphoma patients with BRCA1 Mutation present in 1.47% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Renal Cell Carcinoma +
BRCA1 is altered in 1.87% of renal cell carcinoma patients with BRCA1 Mutation present in 1.44% of all renal cell carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Mesothelioma +
BRCA1 is altered in 1.94% of malignant mesothelioma patients with BRCA1 Mutation present in 1.39% of all malignant mesothelioma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].
Biliary Tract Carcinoma +
BRCA1 is altered in 1.7% of biliary tract carcinoma patients with BRCA1 Mutation present in 1.38% of all biliary tract carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Medulloblastoma +
BRCA1 is altered in 1.2% of medulloblastoma patients with BRCA1 Mutation present in 1.2% of all medulloblastoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Low Grade Ovarian Serous Adenocarcinoma +
BRCA1 is altered in 1.06% of low grade ovarian serous adenocarcinoma patients with BRCA1 Mutation present in 1.06% of all low grade ovarian serous adenocarcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Neuroendocrine Tumor +
BRCA1 is altered in 1.22% of neuroendocrine tumor patients with BRCA1 Mutation present in 0.95% of all neuroendocrine tumor patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Sarcoma +
BRCA1 is altered in 1.22% of sarcoma patients with BRCA1 Mutation present in 0.86% of all sarcoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Esophageal Squamous Cell Carcinoma +
BRCA1 is altered in 0.83% of esophageal squamous cell carcinoma patients with BRCA1 Mutation present in 0.83% of all esophageal squamous cell carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gallbladder Carcinoma +
BRCA1 is altered in 1.57% of gallbladder carcinoma patients with BRCA1 Mutation present in 0.79% of all gallbladder carcinoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Germ Cell Tumor +
BRCA1 is altered in 0.68% of germ cell tumor patients with BRCA1 Mutation present in 0.68% of all germ cell tumor patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Mantle Cell Lymphoma +
BRCA1 is altered in 0.56% of mantle cell lymphoma patients with BRCA1 Mutation present in 0.56% of all mantle cell lymphoma patients [4].
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Breast Fibrocystic Change, Proliferative Type +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for breast fibrocystic change, proliferative type, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and breast fibrocystic change, proliferative type as inclusion criteria, 1 is phase 2 (0 open) [5].
Breast Intraductal Proliferative Lesion +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for breast intraductal proliferative lesion, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and breast intraductal proliferative lesion as inclusion criteria, 1 is phase 2 (0 open) [5].
Bronchogenic Carcinoma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Histiocytic Sarcoma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Intraductal Proliferative Lesion Of The Breast +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for intraductal proliferative lesion of the breast, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and intraductal proliferative lesion of the breast as inclusion criteria, 1 is phase 2 (0 open) [5].
Juvenile Xanthogranuloma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [5].
Langerhans Cell Histiocytosis +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Clear Cell Adenocarcinoma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ovarian Endometrioid Adenocarcinofibroma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinofibroma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and ovarian endometrioid adenocarcinofibroma as inclusion criteria, 1 is phase 3 (1 open) [5].
Peripheral Primitive Neuroectodermal Tumor +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for peripheral primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and peripheral primitive neuroectodermal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Primary Peritoneal High Grade Serous Adenocarcinoma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Mutation and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Vaginal Carcinoma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Vulvar Carcinoma +
BRCA1 Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
